Maegim한국어

온코닉테라퓨틱스

476060KOSDAQSector: Pharma & Biotech
₩11,500▼ 13.14%Market cap ₩522.2BAs of Jul 21, 2026 close · updated once daily
A
Grade A76.8 ptsTop 3% of 2,523 stocks
Financial strength
94.9
Growth momentum
95.8
Price attractiveness
42.5

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

94.9
How much debt does it carry relative to equity?
Debt-to-equity ratio
5.1%
✓ Above median · Top 3.9% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
1762.2%
✓ Above median · Top 6.3% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
23.6%
✓ Above median · Top 6.4% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
21.9%
✓ Above median · Top 3.9% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

95.8
How much did revenue grow in a year?
Revenue growth (YoY)
259.8%
✓ Above median · Top 4.3% in sector
Sector median 6.4%
Did core profits grow in a year?
Operating income change (YoY)
363.0%
✓ Above median · Top 4.2% in sector
Sector median 3.6%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

42.5
Is the price expensive relative to earnings?
P/E (price-to-earnings)
33.1x
✓ Above median · Top 33.1% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
7.25x
✗ Below median · Top 81.9% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15